References
1. Old L.J. Tumor immunology: the first century. Curr Opin Immunol. 1992; 4 (5): 603–37. DOI: https://doi.org/10.1016/0952-7915(92)90034-c
2. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331 (6024): 1565–70. DOI: https://doi.org/10.1126/science.1203486
3. Borroni E.M., Grizzi F. Cancer Immunoediting and beyond in 2021. Int J Mol Sci. 2021; 22 (24): 13275. DOI: https://doi.org/10.3390/ijms222413275
4. Sheu B.C., Hsu S.M., Ho H.N., Lin R.H., Huang SC. Tumor immunology – when a cancer cell meets the immune cells. J Formos Med Assoc. 1999; 98 (11): 730–5. PMID: 10705688.
5. June C.H. Principles of adoptive T-cell cancer therapy. J Clin Invest. 2007; 117 (5): 1204–12. DOI: https://doi.org/10.1172/JCI31446
6. Lindemann A., Herrmann F., Oster W., Mertelsmann R. Lymphokine activated killer cells. Blut. 1989; 59 (4): 375–84. DOI: https://doi.org/10.1007/BF00321208
7. Paijens S.T., Vledder A., de Bruyn M., Nijman H.W. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021; 18 (4): 842–59. DOI: https://doi.org/10.1038/s41423-020-00565-9
8. Mortezaee K., Majidpoor J. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives. Med Oncol. 2022; 39 (9): 131. DOI: https://doi.org/10.1007/s12032-022-01735-7
9. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., Lee C.C., Restifo N.P., Schwarz S.L., Cogdill A.P., Bishop R.J., Kim H., Brewer C.C., Rudy S.F., VanWaes C., Davis J.L., Mathur A., Ripley R.T., Nathan D.A., Laurencot C.M., Rosenberg S.A. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114 (3): 535–46. DOI: https://doi.org/10.1182/blood-2009-03-211714
10. Jogalekar M.P., Rajendran R.L., Khan F., Dmello C., Gangadaran P., Ahn B.C. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022; 13: 925985. DOI: https://doi.org/10.3389/fimmu.2022.925985
11. Ottaviano G., Qasim W. Genome-Edited T Cell Therapies. Hematol Oncol Clin North Am. 2022; 36 (4): 729–44. DOI: https://doi.org/10.1016/j.hoc.2022.03.006
12. Melief C.J.M., Kast W.M. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T-lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev. 1995; 146: 167–77. DOI: https://doi.org/10.1111/j.1600-065x.1995.tb00081.x
13. Ahmed A., Tait S.W.G. Targeting immunogenic cell death in cancer. Mol Oncol. 2020; 14 (12): 2994–3006. DOI: https://doi.org/10.1002/1878-0261.12851
14. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140 (6): 883–99. DOI: https://doi.org/10.1016/j.cell.2010.01.025
15. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009; 15: 425–30. DOI: https://doi.org/10.1158/1078-0432.CCR-08-0149
16. Ataullakhanov R.I., Ushakova E.I., Al Khudhur S.А., Pichugin A.V., Lebedeva E.S. Reprogramming of myeloid cells of the tumor microenvironment – a new approach in the immunotherapy of malignant neoplasms. Immunologiya. 2022; 43 (4): 375–88. DOI: https://doi.org/10.33029/0206-4952-2022-43-4-375-388 (in Russian)
17. Murugina N.E., Murugin V.V., Pashenkov M.V. Antitumor activity of human macrophages activated by NOD1 and TLR4 receptor agonists in vitro. Immunologiya. 2022; 43 (5): 548–57. DOI: https://doi.org/10.33029/0206-4952-2022-43-5-548–557. (in Russian)
18. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013; 342 (6165): 1432–3. DOI: https://doi.org/10.1126/science.342.6165.1432
19. Dougan M., Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009; 27: 83–117. DOI: https://doi.org/10.1146/annurev.immunol.021908.132544
20. St Paul M., Ohashi P.S. The roles of CD8+ T cell subsets in antitumor immunity. Trends Cell Biol. 2020; 30 (9): 695–704. DOI: https://doi.org/10.1016/j.tcb.2020.06.003
21. Oberoi P., Jabulowsky R.A., Bahr-Mahmud H., Wels W. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells. PloS one. 2013; 8 (4): e61267. DOI: https://doi.org/10.1371/journal.pone.0061267
22. Smithson G., Bittick T.H., Chervenak R., Lee S.J., Wolcott R.M. The role of NK cells in the regulation of experimental metastasis in a murine lymphoma system. Journal of leukocyte biology. 1991; 49 (6): 621–9. DOI: https://doi.org/10.1002/jlb.49.6.621
23. Brondz B. D. Interaction of immune lymphocytes with normal and neoplastic tissue cells. Folia Biol. 1964; 10: 164–76. PMID: 14164363.
24. Fuks B.B., Malaitsev V.V., Bogdanova I.M. The lack of generalized immunosuppression in C57BL/6 mice during progressive growth of syngenic T lymphoma EL-4 and Lewis lung carcinoma 3LL. Biull Eksp Biol Med. 1986; 101 (6): 725–8. PMID: 3089345. (in Russian)
25. Kazanskiy D.B., Silaeva Yu.Yu., Kalinina A.A., Zamkova M.A., Khromykh L.M., Persiyantseva N.A., Dzholokhava L.H. Transplantational and specific antitumor immunity in retrospective view: new models based on transgenesis of individual chains of T-cell receptor. Uspehi Molekulârnoj Onkologii. 2016; 3 (1): 14–27. DOI: https://doi.org/10.17650/2313-805X-2016-3-1-14-27 (in Russian)